Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

Press Releases 2007

DNDi Receives $25.7M from the Bill & Melinda Gates Foundation to Develop New Medicines for Neglected Diseases
[ Geneva, Switzerland - December 12, 2007 ]
The Drugs for Neglected Diseases initiative (DNDi) has received a USD 25.7 million grant from the Bill & Melinda Gates Foundation to research and develop new medicines to treat human African trypanosomiasis (HAT), also known as sleeping sickness, and visceral leishmaniasis (VL).

More

The US National Institutes of Health Awards DNDi with a 3-Year Grant Dedicated to the Development of a Low-Cost Treatment for Visceral Leishmaniasis
[ Geneva, Switzerland - November 5, 2007 ]
The National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH), has granted Drugs for Neglected Diseases initiative (DNDi) USD 2.3 million to be disbursed over 3 years for research and development that focuses on developing a low-cost formulation of amphotericin B to treat visceral leishmaniasis.

More

SCYNEXIS and DNDi Enter Landmark Multi-Year Agreement to Identify Drug Candidates to Treat Sleeping Sickness
[Research Triangle Park, USA, and Geneva, Switzerland - November 1, 2007 ]
SCYNEXIS and Drugs for Neglected Diseases initiative (DNDi), have agreed to collaborate on vital drug discovery research and development of affordable and effective therapies for human African trypanosomiasis (also known as sleeping sickness), one of the most devastating diseases in sub-Saharan Africa.

More

DNDi Executive Team Adds Two New Directors, Including Former Abbott VP Shing Chang as New R&D Director
[ Geneva - October 12, 2007 ]
The Drugs for Neglected Diseases initiative (DNDi), a non-profit, drug R&D partnership, announced the appointments of two new members of its executive team: Shing Chang joins as the new Director of Research and Development, and Jean-Pierre Paccaud will serve as Director of Business Development.

More

Advinus Therapeutics and DNDi Join Forces on Drug Discovery and Development for Visceral Leishmanias (Kala Azar)
[ Bangalore and Geneva - October  11, 2007 ]
Advinus Therapeutics (P) Ltd. and Drugs for Neglected Diseases initiative (DNDi), a not-for-profit R&D organization based in Geneva, Switzerland, announced today that they have formed a collaboration for discovery and development of novel therapies for visceral leishmaniasis (kala azar), a fatal infectious disease of developing countries including India.

More

DNDi Welcomes Marcel Tanner As Chair of the Board of Directors Along With New Chair of the Scientific Advisory Committee
[ Geneva - July 13,  2007 ]
Along with 3 newly appointed members to its governance structures, the Drugs for Neglected Diseases initiative (DNDi) today announced the appointments of 2 new chairmen - Dr. Marcel Tanner as the new Chairman of the Board of Directors and Dr. Julio Urbina as the new Chairman of the Scientific Advisory Committee (SAC).

More

New, Once-a-Day Fixed-Dose Combination Against Malaria Now Available
[ Paris - March 1st, 2007 ]
Sanofi-aventis and the non-profit Drugs for Neglected Diseases initiative (DNDi) announced today that ASAQ, the new fixed-dose combination of artesunate (AS) and amodiaquine (AQ), will soon be available throughout sub-Saharan Africa. ASAQ is the first drug developed by the FACT (Fixed-dose, Artemisinin-based Combination Therapy) partners, managed by DNDi in partnership with sanofi-aventis. [Français]

More

Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License